Jubilant Ingrevia commissions new facility for Diketenes, Derivatives

The newly commissioned facility adds additional capacity of ~2000 TPA to produce high-value esters.

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-04-01 06:39 GMT   |   Update On 2024-04-01 06:39 GMT
Advertisement

Noida: Jubilant Ingrevia Limited, has announced the commissioning of a new facility at its manufacturing site for Diketene derivatives at Gajraula, Uttar Pradesh.

As a global, integrated life science products and innovative solutions provider, the Company presently has over 134 products & innovative solutions commercialised. With over four decades of experience, it has developed proficiency across ~35 key chemistry and technology platforms across its businesses: Specialty, Nutrition and Chemical Intermediates.

Advertisement

The newly commissioned facility adds additional capacity of ~2,000 TPA to produce high-value esters.

"This strengthening of the Diketene and derivatives platform marks a natural evolution of strategy in the Specialty Chemicals segment. This business is pivoting towards accelerated growth and higher margins with the introduction of several downstream derivatives. In line with its long-term strategic objectives, Jubilant Ingrevia remains committed to commissioning of future phases of Diketene derivatives. In addition to existing clients the expanded range of diketene derivatives will be aimed at a new category of customers in key international markets, including the U.S and E.U regions," the Company said.

On this occasion, Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited, said, “I am delighted to emphasise our unwavering dedication to specialty chemicals business with the introduction of this new facility. Diketene and derivatives represent an accelerated growth platform for us. We are committed to cultivating a comprehensive range of advanced product portfolio within this segment with about half a dozen existing derivatives and several new ones in pipeline. Today’s announcement marks an inflection in growth as this advancement will bring us closer to satisfying our client’s needs for innovative products and solutions, leveraging a distinctive and specialised chemistry platform”.

"Whereas the existing range of offerings in diketene and derivatives has ramped up markedly, the next iteration of growth shall come from introduction of new products that are presently in the pipeline. The Company’s long-standing association with leading customers in pharmaceuticals, agrochemicals and other industries combined with early efforts to get customer product approvals, are expected to drive major portion of capacity utilisation in the coming months," the release stated.

Read also: Jubilant Radiopharma business receives ANDA approval for Technetium Sulfur Colloid Injection

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News